Research programme: solid tumour therapeutics - NanoSmart

Drug Profile

Research programme: solid tumour therapeutics - NanoSmart

Alternative Names: Autoimmune antinuclear antibodies - Nanosmart; Ewing's sarcoma therapeutics - NanoSmart/Children's Hospital Los Angeles; Human derived antinuclear antibodies - Nanosmart; Tumour necrosis targeted antibodies - NanoSmart

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator NanoSmart Pharmaceuticals
  • Developer Childrens Hospital Los Angeles; NanoSmart Pharmaceuticals
  • Class Antibodies; Immunoconjugates
  • Mechanism of Action RNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ewing's sarcoma
  • New Molecular Entity No

Highest Development Phases

  • No development reported Ewing's sarcoma; Solid tumours

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for research development in Solid-tumours in USA
  • 16 Jul 2016 No recent reports of development identified for research development in Ewing's Sarcoma in USA
  • 30 Jul 2015 NanoSmart's dactinomycin based drug formulation receives Orphan Drug status for Ewing's Sarcoma in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top